Urinary Bladder Neoplasms
-
Subject Areas on Research
-
"Wildcatting" for breakthroughs in urothelial cancer detection and management--a frustrating business.
-
6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity.
-
A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
-
A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers.
-
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
-
A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer.
-
A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer.
-
A cytotoxic proteinase isolated from human lymphocytes.
-
A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
-
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
-
A new assay to quantify in vivo repair of G:T mispairs by base excision repair.
-
A novel XPF -357A>C polymorphism predicts risk and recurrence of bladder cancer.
-
A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population.
-
A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.
-
A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment.
-
A systematic review of regional hyperthermia therapy in bladder cancer.
-
ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer.
-
ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update.
-
ACR Appropriateness Criteria® Pretreatment Staging of Muscle-Invasive Bladder Cancer.
-
Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies.
-
Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
-
Activation of cyclophosphamide for in vitro testing of cell sensitivity.
-
Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
-
Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
-
Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.
-
Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1.
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
-
Anticipatory Positive Urine Tests for Bladder Cancer.
-
Antigenic activity of human urothelial tissue.
-
Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies.
-
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
-
Assessment of quality of cancer-related follow-up care from the cancer survivor's perspective.
-
Assessment of spatial variation of risks in small populations.
-
Assessments of frailty in bladder cancer.
-
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
-
Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer.
-
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
-
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
-
Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer.
-
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
-
Augmentation and substitution enterocystoplasty.
-
Automated versus manual analysis of body composition measures on computed tomography in patients with bladder cancer.
-
Avoiding complications with radical cystectomy.
-
BK virus-associated urinary bladder carcinoma in transplant recipients: productive or nonproductive polyomavirus infections in tumor cells?
-
Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
-
Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
-
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
-
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
-
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
-
Bladder cancer.
-
Bladder cancer. Clinical guidelines in oncology.
-
Bladder cancer. Clinical practice guidelines in oncology.
-
Bladder cancer: chemohyperthermia for bladder cancer--clinically effective?
-
Bladder cancer: race differences in extent of disease at diagnosis.
-
Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent.
-
Bladder leiomyoma: advantages of sonography over computed tomography.
-
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
-
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
-
CLT1 targets bladder cancer through integrin α5β1 and CLIC3.
-
Cancer incidence among patients of the U.S. Veterans Affairs Health Care System.
-
Carcinogenesis in urogenital sites.
-
Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality.
-
Cardiac metastasis from a transitional cell carcinoma: a case report.
-
Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
-
Clinical performance and utility of a DNA methylation urine test for bladder cancer.
-
Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
-
Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
-
Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.
-
Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model.
-
Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines.
-
Combined treatment approaches in regionally advanced bladder cancer.
-
Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population.
-
Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
-
Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
-
Comprehensive handbook for developing a bladder cancer cystectomy database.
-
Comprehensive molecular characterization of urothelial bladder carcinoma.
-
Computed tomographic imaging of microscopic dystrophic calcification in urachal adenocarcinoma.
-
Context-Based Identification of Muscle Invasion Status in Patients With Bladder Cancer Using Natural Language Processing.
-
Continent urinary diversion.
-
Critical review of radical cystectomy and indicators of prognosis.
-
Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
-
Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy.
-
Defective monocyte function in patients with genitourinary carcinoma.
-
Detection of H-ras mutations in urine sediments by a mutant-enriched PCR technique.
-
Detection of metastatic tumors in nude mice: brief communication.
-
Detection of oncornavirus antigenic activity in human urothelial tissues.
-
Development and application of basic research techniques in bladder cancer research.
-
Diagnosis of bladder tumor.
-
Diagnostic tests in urology: urine cytology.
-
Diet and Exercise Are not Associated with Skeletal Muscle Mass and Sarcopenia in Patients with Bladder Cancer.
-
Dietary patterns and health-related quality of life in bladder cancer survivors.
-
Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.
-
Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers.
-
Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma.
-
Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer?
-
Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer?
-
Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.
-
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.
-
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
-
Early detection and measurement of urothelial tumors in mice.
-
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
-
Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
-
Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer.
-
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
-
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.
-
En Bloc Resection of Bladder Tumors: Style or Substance?
-
Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.
-
Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
-
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
-
Evolution of Single-Use Urologic Endoscopy: Benchtop and Initial Clinical Assessment of a New Single-Use Flexible Cystoscope.
-
Exon 3 polymorphisms and haplotypes of O6-methylguanine-DNA methyltransferase and risk of bladder cancer in southern China: a case-control analysis.
-
Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers.
-
Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients.
-
Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy.
-
From Dog's Breakfast to Michelin Guide: Post-bacillus Calmette-Guérin Trials in Non-muscle-invasive Bladder Cancer.
-
Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis.
-
Functional polymorphisms of JWA gene are associated with risk of bladder cancer.
-
G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder.
-
Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.
-
Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer.
-
Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study.
-
Geriatric conditions and treatment burden following diagnosis of non-muscle- invasive bladder cancer in older adults: A population-based analysis.
-
Gleevec, an Abl family inhibitor, produces a profound change in cell shape and migration.
-
Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study.
-
Heat-targeted drug delivery: A promising approach for organsparing treatment of bladder cancer.THERMODOX®.
-
Heated Intravesical Chemotherapy: Biology and Clinical Utility.
-
Hemolytic anemia and metastatic carcinoma: case report and literature review.
-
Hereditary renal cell carcinoma in the rat associated with nonrandom loss of chromosomes 5 and 6.
-
Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?
-
Hyperthermia as a treatment for bladder cancer.
-
Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer.
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
-
Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer.
-
Impact of bladder cancer on health-related quality of life.
-
Impact of marital status in patients undergoing radical cystectomy for bladder cancer.
-
Implications of Cystectomy Travel Distance for Hospital Readmission and Survival.
-
In vitro chemotherapeutic testing of urologic tumors.
-
In vitro chemotherapy testing of transitional cell carcinoma.
-
Incidence and risk factors of stomal complications in patients undergoing cystectomy with ileal conduit urinary diversion for bladder cancer.
-
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
-
Increasing use of positron emission tomography among medicare beneficiaries undergoing radical cystectomy.
-
Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop.
-
Interpreting a study on bladder cancer screening.
-
Intracavitary mitomycin-C in the treatment of superficial urothelial tumors: a preliminary report.
-
Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation.
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
-
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
-
Intravesical therapy use in the high risk patient: practice patterns in an equal access healthcare institution before and after national guidelines.
-
Intravital optical imaging for immune cell tracking after photoimmunotherapy with plasmonic gold nanostars.
-
Investigational therapies for non-muscle invasive bladder cancer.
-
Isolation and characterization of a novel human bladder cancer cell line: BK10.
-
It May Be Time to Abandon Urine Tests for Bladder Cancer.
-
Keyhole limpet hemocyanin: structural and functional characterization of two different subunits and multimers.
-
Laparoscopic hand assisted radical cystectomy with ileal conduit urinary diversion.
-
Laparoscopy-assisted robotic radical cystoprostatectomy with ileal conduit urinary diversion for muscle-invasive bladder cancer: initial two cases.
-
Lesions of bone and bladder cancer.
-
Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review.
-
Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.
-
Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer.
-
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
-
Loss of uteroglobin expression in prostate cancer: relationship to advancing grade.
-
Lymphoepithelioma-like carcinoma of the urinary bladder.
-
Magnetic fluid hyperthermia for bladder cancer: a preclinical dosimetry study.
-
Maintenance bacillus Calmette-Guérin: why is there continued debate?
-
Management of patients with concurrent primary tumors of bladder and prostate.
-
Management of primary squamous cell carcinoma at the mucocutaneous junction of an ileal conduit.
-
Maximizing outcomes in genitourinary cancers across the treatment continuum.
-
Methoxyflurane-induced renal dysfunction.
-
Microscopic hematuria as a predictive factor for detecting bladder cancer at cystoscopy in women with irritative voiding symptoms.
-
Molecular cytogenetic analysis of the bladder carcinoma cell line BK-10 by spectral karyotyping.
-
Molecular markers in bladder cancer.
-
Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial.
-
Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
-
Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?
-
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.
-
N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines.
-
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
-
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
-
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
-
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.
-
National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results.
-
New and emerging therapies for bone metastases in genitourinary cancers.
-
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
-
Non-Hodgkin's lymphoma with bladder involvement.
-
Novel suppressor loci on chromosome 14q in primary bladder cancer.
-
Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.
-
Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction.
-
Open surgical partial nephrectomy for upper tract urothelial carcinoma.
-
Optimal staging procedures, including imaging, to define prognosis of bladder cancer.
-
Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer.
-
Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder.
-
Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.
-
Overview of bladder cancer trials in the Cancer and Leukemia Group B.
-
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
-
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
-
Partitioning of time trends in prevalence and mortality of bladder cancer in the United States.
-
Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro.
-
Perioperative Intravesical Chemotherapy for Patients WithNon-Muscle-invasive Bladder Cancer: Understanding the Extent of and Sources of Variation in Guideline-recommended Use.
-
Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
-
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
-
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
-
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
-
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
-
Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience.
-
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
-
Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.
-
Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC).
-
Post-traumatic stress disorder symptoms in non-muscle-invasive bladder cancer survivors: A population-based study.
-
Predicting Short-term Outcomes After Radical Cystectomy Based on Frailty.
-
Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival.
-
Preoperative immunonutrition prior to radical cystectomy: a pilot study.
-
Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival.
-
Primary non-urachal adenocarcinoma of the bladder.
-
Prostatic disorders: MR imaging at 1.5 T.
-
Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review.
-
Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee.
-
Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
-
Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder.
-
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
-
Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
-
Re: Jiang et al.: Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk (Urology 2010;76:765).
-
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.
-
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
-
Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts.
-
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
-
Relationships among uncertainty, post-traumatic stress disorder symptoms, and quality of life in non-muscle-invasive bladder cancer survivors.
-
Reply by Authors.
-
Reply to 'It May be Time to Abandon Urine Tests for Bladder Cancer'.
-
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
-
Response of human urothelium to chemical carcinogens in vitro.
-
Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
-
Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study.
-
Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis.
-
Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
-
Small cell bladder cancer: should we consider prophylactic cranial irradiation?
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
-
Squamous carcinoma of urinary bladder.
-
Statistical analysis of cytologic features useful in separation of metastatic urothelial carcinoma from other metastatic epithelial malignancies.
-
Statistically adjusted estimates of geographic mortality profiles.
-
Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
-
Superficial bladder cancer epidemiology, diagnosis and management.
-
Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers.
-
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
-
Systemic chemotherapy for urothelial cancer.
-
TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract.
-
Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.
-
The Cost to Medicare of Bladder Cancer Care.
-
The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.
-
The Stability of Physician-Specific Episode Costs for Urologic Cancer Surgery: Implications for Urologists Under the Merit-Based Incentive Program.
-
The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy.
-
The association of oncogenic human papillomaviruses with urologic malignancy. The controversies and clinical implications.
-
The characteristics of bladder cancer after radiotherapy for prostate cancer.
-
The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients.
-
The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient.
-
The histopathology of vesical diverticula.
-
The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment.
-
The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
-
The neuronatin gene resides in a "micro-imprinted" domain on human chromosome 20q11.2.
-
The predictive value of 2,-4, dinitrochlorobenzene skin testing in patients with bilharzial bladder cancer.
-
The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction.
-
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.
-
The role of flow cytometry in the management of bladder cancer.
-
The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
-
The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.
-
The use of hyperthermia in the treatment of bladder cancer.
-
The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.
-
Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer.
-
Thermal dosimetry for bladder hyperthermia treatment. An overview.
-
Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma.
-
Thromboembolism and bleeding in bladder cancer.
-
Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma.
-
Toward improved effectiveness of bladder cancer immunotherapy.
-
Transitional cell carcinoma in a prostatic remnant 10 years after radical cystectomy.
-
Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.
-
Treatment of high-stage bladder cancer: case for adjunctive chemotherapy.
-
Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.
-
Treatment of superficial carcinoma of the bladder.
-
Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
-
Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study.
-
Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy.
-
Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
-
Urologic surgery.
-
Use of an Electronic Medical Record to Assess Patient-Reported Morbidity Following Ureteroscopy.
-
Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
-
Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma.
-
VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.
-
Vaginal Complications after Cystectomy: Results from a Medicare Sample.
-
Keywords of People